Klaviyo, Inc.

For the period ended Jun 30, 2025. Filed Aug 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 5, 2025

KVYO$20.43-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)

Series A Common Stock · Series B Common Stock · Additional Paid-In Capital · Total Stockholders’ Equity
Number of Shares · $0.001 Par Value · Number of Shares · $0.001 Par Value · Accumulated Deficit
Balance as of March 31, 2024	70,065,833	$70			193,969,875		$194			$1,749,113		$(811,925)			$937,452
Issuance of common stock upon exercise of common stock options	—	—		669,295		1		1,112		—	1,113
Issuance of common stock upon vesting of restricted stock units	286,854	1		1,126,186		1		(2)		—	—
Issuance of common stock upon exercise of collaboration agreement warrants	—	—		344,381		—		3		—	3
Issuance of common stock under the employee stock purchase plan	206,156		—			—			—		4,362			—		4,362
Vested warrants related to collaboration agreement	—	—		—		—		8,100		—	8,100
Stock-based compensation expense	—	—		—		—		35,316		—	35,316
Tax withholdings on settlement of stock-based awards	(28,017)	—		(48,796)		—		(1,904)		—	(1,904)
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards	1,979,912	2			(1,979,912)		(2)			—	—		—
Net loss	—	—			—		—			—	(4,942)		(4,942)
Balance as of June 30, 2024	72,510,738	$73			194,081,029		$194			$1,796,100		$(816,867)			$979,500
Balance as of March 31, 2025	94,574,036		$95			180,983,334			$181		$1,922,930			$(859,274)		$1,063,932
Issuance of common stock upon exercise of common stock options	—		—			21,664,082			22		567			—		589
Issuance of common stock upon vesting of restricted stock units	1,213,329		1			713,692			1		(2)			—		—
Issuance of common stock upon exercise of collaboration agreement warrants	—		—			344,382			—		4			—		4
Issuance of common stock under the employee stock purchase plan	275,800		—			—			—		6,093			—		6,093
Vested warrants related to the collaboration agreement	—		—			—			—		8,100			—		8,100
Stock-based compensation expense	—		—			—			—		46,884			—		46,884
Tax withholdings on settlement of stock-based awards	(69,484)		—			(63,987)			—		(4,569)			—		(4,569)
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards	20,884,249		21			(20,884,249)			(21)		—			—		—
Net loss	—		—			—			—		—			(24,281)		(24,281)
Balance as of June 30, 2025	116,877,930		$117			182,757,254			$183		$1,980,007			$(883,555)		$1,096,752

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (cont.)

Series A Common Stock · Series B Common Stock · Additional Paid-In Capital · Total Stockholders’ Equity
Number of Shares · $0.001 Par Value · Number of Shares · $0.001 Par Value · Accumulated Deficit
Balance as of January 1, 2024	40,841,834	$41	218,524,009	$219		$1,713,560			$(799,043)			$914,777
Issuance of common stock upon exercise of common stock options	—	—	4,384,377	4	4,673			—		4,677
Issuance of common stock upon vesting of restricted stock units	322,527	1	2,100,174	2	(3)		—		—
Issuance of common stock upon exercise of collaboration agreement warrants	—	—	688,763	—	7			—		7
Issuance of common stock under the employee stock purchase plan	206,156	—	—	—		4,362			—			4,362
Vested warrants related to collaboration agreement	—	—	—	—	16,200			—		16,200
Stock-based compensation expense	—	—	—	—	71,070			—		71,070
Tax withholdings on settlement of stock-based awards	(43,185)	—	(432,888)	—	(13,769)			—		(13,769)
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards	31,183,406	31	(31,183,406)	(31)		—			—		—
Net loss	—	—	—	—		—			(17,824)			(17,824)
Balance as of June 30, 2024	72,510,738	$73	194,081,029	$194		$1,796,100			$(816,867)			$979,500
Balance as of January 1, 2025	88,956,301	$89	183,801,332	$184		$1,878,899			$(845,185)			$1,033,987
Issuance of common stock upon exercise of common stock options	—	—	22,584,809	23		1,442			—			1,465
Issuance of common stock upon vesting of restricted stock units	2,098,709	2	1,456,112	2		(4)			—			—
Issuance of common stock upon exercise of collaboration agreement warrants	—	—	688,764	—		7			—			7
Issuance of common stock under the employee stock purchase plan	275,800	—	—	—		6,093			—			6,093
Vested warrants related to the collaboration agreement	—	—	—	—		16,200			—			16,200
Stock-based compensation expense	—	—	—	—		86,318			—			86,318
Tax withholdings on settlement of stock-based awards	(116,659)	—	(109,984)	—		(8,948)			—			(8,948)
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards	25,663,779	26	(25,663,779)	(26)		—			—			—
Net loss	—	—	—	—		—			(38,370)			(38,370)
Balance as of June 30, 2025	116,877,930	$117	182,757,254	$183		$1,980,007			$(883,555)			$1,096,752

The accompanying notes are an integral part of these condensed consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.